Company Overview of Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; and Ryanodex injectable suspension for the treatment of malignant hyperthermia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma;; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, whi...
50 Tice Boulevard
Woodcliff Lake, NJ 07677
Founded in 2007
Key Executives for Eagle Pharmaceuticals Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $449.6K
Chief Financial Officer
Total Annual Compensation: $265.9K
Chief Medical Officer and Head of Research & Development
Total Annual Compensation: $303.8K
Chief Scientific Officer
Total Annual Compensation: $352.4K
Compensation as of Fiscal Year 2014.
Eagle Pharmaceuticals Inc. Key Developments
Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing
Jul 23 15
Eagle Pharmaceuticals Inc. announced that the 505 (b)(2) New Drug Application (NDA) for its novel ready-to-use bivalirudin product has been accepted for filing by the U.S. Food and Drug Administration (FDA). This 505(b)(2) NDA requests FDA approval of Eagle’s RTU bivalirudin product for the treatment of patients: undergoing percutaneous coronary intervention (PCI) with use of glycoprotein IIb/IIIa inhibitor, undergoing PCI with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome, or with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Eagle’s RTU bivalirudin product, which contains the same active ingredient as Angiomax, is administered as an IV solution at the same dose and rate. Eagle’s liquid formulation will allow for immediate administration, with no reconstitution nor initial dilution required, reducing work flow and the risk of dosing errors. Eagle’s intellectual property pertaining to RTU bivalirudin includes two issued patents and an additional patent pending at the U.S. Patent and Trademark Office.
Eagle Pharmaceuticals Inc.(NasdaqGM:EGRX) added to Russell 2000 Index
Jun 30 15
Eagle Pharmaceuticals Inc. will be added to Russell 2000 Index
Eagle Pharmaceuticals Inc.(NasdaqGM:EGRX) added to Russell 3000 Index
Jun 30 15
Eagle Pharmaceuticals Inc. will be added to the Russell 3000 Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries